BWAY:NSD-Brainsway Ltd (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 5.90

Change

+0.05 (+0.85)%

Market Cap

USD 0.06B

Volume

2.70K

Average Target Price

USD 13.00 (+120.34%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+0.04 (+0.01%)

USD44.71B 61.31 36.64
DXCM DexCom, Inc

+1.99 (+0.50%)

USD38.32B 173.65 108.43
IDXX IDEXX Laboratories, Inc

-1.31 (-0.34%)

USD32.86B 69.09 46.81
EXAS Exact Sciences Corporation

+2.31 (+2.32%)

USD14.97B N/A N/A
GH Guardant Health, Inc

+2.25 (+2.06%)

USD10.84B N/A N/A
ICLR ICON Public Limited Company

+2.67 (+1.44%)

USD9.79B 29.89 20.21
QDEL Quidel Corporation

+16.36 (+8.24%)

USD8.84B 55.27 34.27
PRAH PRA Health Sciences, Inc

-0.87 (-0.88%)

USD6.34B 29.56 17.69
NTRA Natera, Inc

+2.62 (+3.74%)

USD5.89B N/A N/A
SYNH Syneos Health, Inc

-0.42 (-0.79%)

USD5.55B 28.65 16.75

ETFs Containing BWAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.49% 20% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.49% 20% F 18% F
Trailing 12 Months  
Capital Gain -35.80% 22% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.80% 22% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.73% N/A N/A 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.73% N/A N/A 18% F
Risk Return Profile  
Volatility (Standard Deviation) 15.52% N/A N/A 80% B-
Risk Adjusted Return -62.69% N/A N/A 11% F
Market Capitalization 0.06B 27% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.12 68% D+ 38% F
Price / Cash Flow Ratio -8.77 68% D+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -36.40% 47% F 29% F
Return on Invested Capital -52.33% 36% F 18% F
Return on Assets -10.82% 51% F 26% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.54 88% B+ 84% B
Short Percent N/A N/A N/A N/A N/A
Beta 0.61 89% B+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.